Results 71 to 80 of about 19,722 (182)
Nanotechnology in Hematology: Enhancing Therapeutic Efficacy With Nanoparticles
ABSTRACT Background and Aims Hematological malignancies, such as leukemia, lymphoma, and multiple myeloma, contribute significantly to global cancer diagnoses. Despite progress in conventional therapies, such as chemotherapy and immunotherapy, these treatments face limitations, including nonspecific targeting, side effects, and drug resistance. The aim
Nima Torabi Fard+3 more
wiley +1 more source
α‐Synuclein in Parkinson's Disease: From Bench to Bedside
ABSTRACT α‐Synuclein (α‐syn), a pathological hallmark of PD, is emerging as a bridging element at the crossroads between neuro/immune‐inflammatory responses and neurodegeneration in PD. Several evidence show that pathological α‐syn accumulates in neuronal and non‐neuronal cells (i.e., neurons, microglia, macrophages, skin cells, and intestinal cells ...
Gabriele Bellini+8 more
wiley +1 more source
Using current standard‐of‐care tests used in clinical practice, 20%–30% of B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL) patients remain unclassified. These patients are grouped into a heterogeneous category named B‐other ALL and are all treated with the same intensity. The application of RNA‐seq, together with the integration of standard‐of‐
Clara Vicente‐Garcés+12 more
wiley +1 more source
Background Philadelphia chromosome, a hallmark of chronic myeloid leukemia (CML), plays a key role in disease pathogenesis. It reflects a balanced reciprocal translocation between long arms of chromosomes 9 and 22 involving BCR and ABL1 genes ...
S. Dasgupta+8 more
semanticscholar +1 more source
Simultaneous inhibition of multiple oncogenic signaling pathways is crucial for managing refractory cancers. This study introduces two unique core-shell nanoparticle (CS-NP) systems crafted from natural proteins that simultaneously target two crucial ...
Archana Payickattu Retnakumary+10 more
doaj +1 more source
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +1 more source
Chronic Myeloid Leukemia with Rare e1a3 BCR-ABL Transcript
Chronic myelogenous leukemia (CML) results from neoplastic transformation of a hematopoietic stem cell. It is cytogenetically characterized by the presence of Philadelphia chromosome which results from reciprocal translocation t(9;22) that juxtaposes ...
Najia Tabassum+3 more
doaj
Introduction: Chronic myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome (Ph), resulting from the balanced reciprocal translocation t(9;22)(q34;q11).
Aya Bonilla, Carlos Alberto +10 more
doaj
Breakthrough in Degradation of BCR-ABL Fusion Protein for the Treatment of Cancer [PDF]
openaire +3 more sources
Objective To investigate the laboratory and clinical characteristics of acute lymphoblastic leukemia (ALL) with e1a3 BCR-ABL fusion protein. Methods The clinical data, and results of bone marrow cytology, flow cytometry, karyotyping, fluorescence in situ hybridization (FISH) and real-time fluorescence quantitative PCR of 2 ALL cases with e1a3 BCR-ABL ...
CHEN Siyu+6 more
openaire +1 more source